coumarin 6 has been researched along with curcumin in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Jia, Y; Liu, S; Liu, X; Pan, W; Tian, C; Wang, H; Wang, Y; Yan, J | 1 |
Aguilera-Garrido, A; Boulaiz, H; Galisteo-González, F; Marchal, JA; Molina-Bolívar, JA; Navarro, SA; Ramírez, A | 1 |
Duan, D; Jiang, Y; Li, Y; Mu, H; Ni, L; Sun, K; Wang, A; Wu, Z; Yan, X; Zhang, L | 1 |
3 other study(ies) available for coumarin 6 and curcumin
Article | Year |
---|---|
Co-delivery of docetaxel and curcumin prodrug via dual-targeted nanoparticles with synergistic antitumor activity against prostate cancer.
Topics: Aconitic Acid; Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Coumarins; Curcumin; Docetaxel; Drug Delivery Systems; Drug Liberation; Drug Stability; Drug Synergism; Endocytosis; Humans; Inhibitory Concentration 50; Lactic Acid; Male; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Particle Size; Peptides; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Prodrugs; Prostatic Neoplasms; Proton Magnetic Resonance Spectroscopy; Taxoids; Thiazoles | 2017 |
Albumin-covered lipid nanocapsules exhibit enhanced uptake performance by breast-tumor cells.
Topics: Breast Neoplasms; Cell Proliferation; Cell Survival; Coumarins; Curcumin; Drug Liberation; Endocytosis; Female; Humans; Lipids; MCF-7 Cells; Nanocapsules; Serum Albumin; Thiazoles | 2018 |
Trastuzumab- and Fab' fragment-modified curcumin PEG-PLGA nanoparticles: preparation and evaluation in vitro and in vivo.
Topics: Animals; Cell Death; Cell Line, Tumor; Coumarins; Curcumin; Endocytosis; Female; Flow Cytometry; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Mice, Inbred BALB C; Microscopy, Fluorescence; Nanoparticles; Polyesters; Polyethylene Glycols; Rats, Sprague-Dawley; Thiazoles; Tissue Distribution; Trastuzumab | 2018 |